Cigna Group (CI) stock
CINYSEHospital & Medical Service PlansFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3021% below fair value
$301.45−1.68 (-0.55%)
Close on Nov 11, 2026Market cap $79.66BP/E 13.3Yield 2.00%
Cigna EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Cigna's EPS for the twelve months ending Sep 30, 2026 was $22.66, down 0.0% year over year. For fiscal 2025 it was $22.18, up 83.0% from the year before. The highest annual figure on record is $22.96 in fiscal 2020.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.18 | +83.0% |
| FY2024 | Dec 31, 2024 | $12.12 | -30.3% |
| FY2023 | Dec 31, 2023 | $17.39 | -18.8% |
| FY2022 | Dec 31, 2022 | $21.41 | +35.9% |
| FY2021 | Dec 31, 2021 | $15.75 | -31.4% |
| FY2020 | Dec 31, 2020 | $22.96 | +70.8% |
| FY2019 | Dec 31, 2019 | $13.44 | +27.5% |
| FY2018 | Dec 31, 2018 | $10.54 | +20.2% |
| FY2017 | Dec 31, 2017 | $8.77 | +22.0% |
| FY2016 | Dec 31, 2016 | $7.19 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $5.47 | -21.6% |
| Q2 FY2026 | Jun 30, 2026 | $6.29 | +10.2% |
| Q1 FY2026 | Mar 31, 2026 | $6.26 | +29.1% |
| Q4 FY2025 | Dec 31, 2025 | $4.64 | -9.6% |
| Q3 FY2025 | Sep 30, 2025 | $6.98 | +165.4% |
| Q2 FY2025 | Jun 30, 2025 | $5.71 | +4.8% |
| Q1 FY2025 | Mar 31, 2025 | $4.85 | – |
| Q4 FY2024 | Dec 31, 2024 | $5.13 | +47.0% |
| Q3 FY2024 | Sep 30, 2024 | $2.63 | -44.5% |
| Q2 FY2024 | Jun 30, 2024 | $5.45 | +10.8% |
| Q1 FY2024 | Mar 31, 2024 | -$0.97 | -122.9% |
| Q4 FY2023 | Dec 31, 2023 | $3.49 | -10.7% |
| Q3 FY2023 | Sep 30, 2023 | $4.74 | -47.2% |
| Q2 FY2023 | Jun 30, 2023 | $4.92 | +0.6% |
| Q1 FY2023 | Mar 31, 2023 | $4.24 | +13.7% |
| Q4 FY2022 | Dec 31, 2022 | $3.91 | +15.0% |
| Q3 FY2022 | Sep 30, 2022 | $8.97 | +86.9% |
| Q2 FY2022 | Jun 30, 2022 | $4.89 | +15.1% |
| Q1 FY2022 | Mar 31, 2022 | $3.73 | +13.0% |
| Q4 FY2021 | Dec 31, 2021 | $3.40 | -70.3% |
| Q3 FY2021 | Sep 30, 2021 | $4.80 | +27.0% |
| Q2 FY2021 | Jun 30, 2021 | $4.25 | -10.1% |
| Q1 FY2021 | Mar 31, 2021 | $3.30 | +4.8% |
| Q4 FY2020 | Dec 31, 2020 | $11.45 | +340.4% |
| Q3 FY2020 | Sep 30, 2020 | $3.78 | +5.9% |
| Q2 FY2020 | Jun 30, 2020 | $4.73 | +27.8% |
| Q1 FY2020 | Mar 31, 2020 | $3.15 | -11.5% |
| Q4 FY2019 | Dec 31, 2019 | $2.60 | +372.7% |
| Q3 FY2019 | Sep 30, 2019 | $3.57 | +13.7% |
| Q2 FY2019 | Jun 30, 2019 | $3.70 | +12.5% |
| Q1 FY2019 | Mar 31, 2019 | $3.56 | -4.3% |
| Q4 FY2018 | Dec 31, 2018 | $0.55 | -48.6% |
| Q3 FY2018 | Sep 30, 2018 | $3.14 | +42.1% |
| Q2 FY2018 | Jun 30, 2018 | $3.29 | +4.4% |
| Q1 FY2018 | Mar 31, 2018 | $3.72 | +61.7% |
| Q4 FY2017 | Dec 31, 2017 | $1.07 | – |
| Q3 FY2017 | Sep 30, 2017 | $2.21 | – |
| Q2 FY2017 | Jun 30, 2017 | $3.15 | – |
| Q1 FY2017 | Mar 31, 2017 | $2.30 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?